![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » VIROPHARMA ANNOUNCES SUBMISSION OF IND APPLICATION FOR HCV-796
VIROPHARMA ANNOUNCES SUBMISSION OF IND APPLICATION FOR HCV-796
ViroPharma has announced that its partner in the development of antiviral compounds targeting hepatitis C (HCV), Wyeth Pharmaceuticals, a division of Wyeth has submitted an investigational new drug (IND) application to the FDA to evaluate ViroPharma's compound HCV-796, a novel polymerase inhibitor, as a potential new product to treat hepatitis C.
Under this IND, a protocol has been prepared to assess the safety and tolerability of HCV-796 in healthy adult volunteers, as well as to gather pharmacokinetic data. Preclinical studies have shown HCV-796 may be more potent than other anti-HCV compounds developed to date between the two companies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct